Regal Assets Analytics

About GeoTeam

GeoInvesting was founded in 2007 to bring Tier One Quality Microcap research and actionable stock ideas to its Premium Subscribers. Information is distributed to subscribers through a platform featuring a robust catalogue of research. Model portfolios, research updates and idea generation complement one another to build a full picture of companies in GeoInvesting's coverage universe. GeoInvesting has also built a high-quality investor network of research contributors that generate ideas and pitches for subscribers. GeoInvesting research is conducted through intense due diligence, live management interviews, a deep analysis of SEC filings, press releases and conference calls. The company has also played a big part in helping investors understand risk and portfolio protection.

GeoWire Monthly, Vol. 3, Issue No. 1, January 2023

By |2023-01-13T13:55:12-05:00January 11th, 2023|

We’ll be getting back to the normal Monthly GeoWire format next month, but we wanted to take this first edition of the new year to look back at everything we were up to in 2022. Don’t worry, we will be getting back to our normal video format starting in February.  This month’s GeoWire will be split up into 2 issues -  one today, and the other next week. A lot happened in 2022, and we thought it was best to split it up into two separate posts to be able to put adequate focus on the themes we want to discuss. This Week: The stock market and recession, our new Model Recession Portfolios, and still the chance to participate in our special offer for 2023.

Non-GAAP – The Pragmatic Approach to Earnings Analysis [GeoWire Weekly No. 66]

By |2023-01-09T08:07:03-05:00January 8th, 2023|

In 2016 we addressed the dichotomous approach to understanding the differences between generally accepted accounting principles (GAAP) and non-GAAP earnings. There are ways they should be scrutinized when trying to get a sense if numbers being reported by a company are a true representation of what is going on at the net income level. Non-GAAP financials are also referred to as “adjusted.”  For example, “adjusted earnings per share (EPS) or “adjusted earnings before interest taxes & depreciation & amortization (EBITDA). Because we plan on delving into this subject in a Tweet thread that we anticipate will engage our investor network and extensions thereof, we feel it is a good idea to give another primer on the subject, especially since GeoInvesting’s Premium Subscriber base has grown substantially since 2016. If part of your investment strategy is executing bullish or bearish short-term stock trades on earnings report news flow, it’s extremely important to understand if the GAAP and Non-GAAP earnings per share numbers being reported in a press release are “clean”.

SanaCurrents on X4 Pharma’s (XFOR) small molecule to treat chronic neutropenia

By |2023-01-09T08:31:40-05:00January 7th, 2023|Tags: |

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Probability Sentiment SUMMARY X4 Pharmaceuticals, Inc.’s (NASDAQ:XFOR) mavorixafor posted impressive clinical [...]

When Cyclical Stocks Become Relevant, Here’s A Strategy You Can Use [GeoWire Weekly No. 65]

By |2023-01-03T13:58:16-05:00January 3rd, 2023|

The sales, earnings and thus share prices of cyclical stocks (cyclicals) tend to fluctuate with the overall economy and are associated with industries that are heavily affected by the economic cycle and consumer demand. (Example: stocks in the automotive, airline, hospitality, housing, building material and retail industries). Cyclicals do well when the economy is strong and consumer demand is high, and conversely, can suffer when the economy is weak and consumer demand is low. This makes them an attractive investment class for those who are skilled at identifying economic trends or when it becomes fairly obvious that an economy is peaking or bottoming.

When Operating Leverage Is Considered A Multibagger Catalyst (An InfoArb Christmas Present)? [GeoWire Weekly No. 64]

By |2022-12-28T09:39:28-05:00December 26th, 2022|

While it’s certainly been a tough investment environment in 2022, RWWI is now sitting at $20 per share, an all-time high, and 5 times its price at the time of the article. It has basically turned into a quintessential case study for putting an emphasis on operating leverage trends as a potential way to spot a multibagger in the making. Now that growth at a reasonable price (GARP) investing is back in focus, we are going to keep our eye open for these types of setups. There were other bullish factors at play, such as its recurring revenue model, its position as a prime acquisition target, and very unique relationship with Autodesk, Inc. (NASDAQ:ADSK) for which it was not only a reseller but also a developer of add-ons to extend the utility of the software it sold. So, this brings us to another stock on which we’d like to begin to put a spotlight based on operating leverage. We’d like to do a similar analysis, more comprehensive analysis like the one we put out on RWWI, but we have yet to look at additional factors that might lead us to write a full RFT.

Recession Proof and Recession Resistant Stocks in Focus [GeoWire Weekly No. 63]

By |2023-02-03T15:55:07-05:00December 18th, 2022|

In this stock market environment, think of a dividend as a welcome gift that tempers any pain you might be going through as you wait for things to come back to normal. Furthermore, we believe the company’s involvement in the healthcare services industry allows it to possess traits that make it “Recession Proof.” A little later in this post, we refer you to a forum clip where we touch upon what it means for a company to be recession proof versus recession resistant. So, we spoke with a company representative in early November to pre-qualify it for a Live Fireside Chat that will be accessible by and exclusively archived for you. We are in the process of scheduling this call, as we believe the stock has the potential to double.  We've clipped out a section of our December 2022 Monthly Open Forum where Maj talks about the stock and the reasons why there is a potential for it to claim a spot on our Favorites list. 

SanaCurrents on PDUFA decision for Tarsus’ (TARS) drug to treat dry eye caused by mites

By |2022-12-19T10:11:18-05:00December 17th, 2022|Tags: |

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Probability Sentiment SUMMARY Staying focused on an FDA approval paid off [...]

Go to Top